Analysts had projected Yescarta sales of $98.5 million. "Gilead Sciences Reports Q1 Results Above Wall Street Targets," at 2109 GMT, misstated that they had projected sales of $98.5 billion in the eighth paragraph.

(END) Dow Jones Newswires

May 02, 2019 23:27 ET (03:27 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Gilead Sciences Charts.